[Progressive multiple sclerosis. Evaluation of the effectiveness of total lymph node irradiation]. 1991

A Buffoli, and E Micheletti, and R Capra, and F Mattioli, and N Marcianò
Cattedra di Radioterapia, Università di Brescia.

A long-lasting immunological suppression action seems to be produced by total lymphoid irradiation; some authors emphasize the favorable effect of this treatment on chronic progressive multiple sclerosis. In order to evaluate the actual role of TLI, 6 patients affected with chronic progressive multiple sclerosis were submitted to TLI with shaped and personalized fields at the Instituto del Radio, University of Brescia, Italy. The total dose delivered was 19.8 Gy in 4 weeks, 1.8 Gy/day, 5d/w; a week elapsed between the first and the second irradiation course. Disability according to Kurtzke scale was evaluated, together with blood lymphocyte count and irradiation side-effects, over a mean follow-up period of 20.8 months (range: 13-24). Our findings indicate that: a) disease progression was not markedly reduced by TLI; b) steroid hormones responsivity was restored after irradiation, and c) side-effects were mild and tolerable.

UI MeSH Term Description Entries
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D009103 Multiple Sclerosis An autoimmune disorder mainly affecting young adults and characterized by destruction of myelin in the central nervous system. Pathologic findings include multiple sharply demarcated areas of demyelination throughout the white matter of the central nervous system. Clinical manifestations include visual loss, extra-ocular movement disorders, paresthesias, loss of sensation, weakness, dysarthria, spasticity, ataxia, and bladder dysfunction. The usual pattern is one of recurrent attacks followed by partial recovery (see MULTIPLE SCLEROSIS, RELAPSING-REMITTING), but acute fulminating and chronic progressive forms (see MULTIPLE SCLEROSIS, CHRONIC PROGRESSIVE) also occur. (Adams et al., Principles of Neurology, 6th ed, p903) MS (Multiple Sclerosis),Multiple Sclerosis, Acute Fulminating,Sclerosis, Disseminated,Disseminated Sclerosis,Sclerosis, Multiple
D005069 Evaluation Studies as Topic Works about studies that determine the effectiveness or value of processes, personnel, and equipment, or the material on conducting such studies. Critique,Evaluation Indexes,Evaluation Methodology,Evaluation Report,Evaluation Research,Methodology, Evaluation,Pre-Post Tests,Qualitative Evaluation,Quantitative Evaluation,Theoretical Effectiveness,Use-Effectiveness,Critiques,Effectiveness, Theoretical,Evaluation Methodologies,Evaluation Reports,Evaluation, Qualitative,Evaluation, Quantitative,Evaluations, Qualitative,Evaluations, Quantitative,Indexes, Evaluation,Methodologies, Evaluation,Pre Post Tests,Pre-Post Test,Qualitative Evaluations,Quantitative Evaluations,Report, Evaluation,Reports, Evaluation,Research, Evaluation,Test, Pre-Post,Tests, Pre-Post,Use Effectiveness
D005260 Female Females
D005500 Follow-Up Studies Studies in which individuals or populations are followed to assess the outcome of exposures, procedures, or effects of a characteristic, e.g., occurrence of disease. Followup Studies,Follow Up Studies,Follow-Up Study,Followup Study,Studies, Follow-Up,Studies, Followup,Study, Follow-Up,Study, Followup
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000328 Adult A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available. Adults
D015182 Lymphatic Irradiation External or interstitial irradiation to treat lymphomas (e.g., Hodgkin's and non-Hodgkin's lymphomas) and lymph node metastases and also some autoimmune diseases, such as rheumatoid arthritis. Lymphatic Radiation Therapy,Lymphoid Irradiation,Radiotherapy, Lymphatic,Irradiation, Lymphatic,Irradiation, Lymphoid,Lymphatic Radiotherapy,Radiation Therapy, Lymphatic,Therapy, Lymphatic Radiation,Irradiations, Lymphatic,Irradiations, Lymphoid,Lymphatic Irradiations,Lymphatic Radiation Therapies,Lymphatic Radiotherapies,Lymphoid Irradiations,Radiation Therapies, Lymphatic,Radiotherapies, Lymphatic,Therapies, Lymphatic Radiation

Related Publications

A Buffoli, and E Micheletti, and R Capra, and F Mattioli, and N Marcianò
June 1986, Lancet (London, England),
A Buffoli, and E Micheletti, and R Capra, and F Mattioli, and N Marcianò
January 1984, Annals of the New York Academy of Sciences,
A Buffoli, and E Micheletti, and R Capra, and F Mattioli, and N Marcianò
November 1997, Journal of the neurological sciences,
A Buffoli, and E Micheletti, and R Capra, and F Mattioli, and N Marcianò
March 1993, Annals of the New York Academy of Sciences,
A Buffoli, and E Micheletti, and R Capra, and F Mattioli, and N Marcianò
January 1995, Acta neurologica Scandinavica,
A Buffoli, and E Micheletti, and R Capra, and F Mattioli, and N Marcianò
February 1994, Journal of neurology, neurosurgery, and psychiatry,
A Buffoli, and E Micheletti, and R Capra, and F Mattioli, and N Marcianò
August 1986, Lancet (London, England),
A Buffoli, and E Micheletti, and R Capra, and F Mattioli, and N Marcianò
January 1988, International journal of radiation oncology, biology, physics,
A Buffoli, and E Micheletti, and R Capra, and F Mattioli, and N Marcianò
February 1991, Medicina clinica,
A Buffoli, and E Micheletti, and R Capra, and F Mattioli, and N Marcianò
February 2023, Cancers,
Copied contents to your clipboard!